Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA)

AstraZeneca106 enrolled

Overview

First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy in Asia Area

Study Design: The study is an observational review of medical records of patients diagnosed with unresectable stage III NSCLC in Taiwan, participating in an early access program (EAP). Physicians having treated patients in the EAP will be asked to recruit these patients to have their data abstracted from their medical records. Data will only be collected from routine clinical care. Data Source(s): Centre staff will extract de-identified data from patient's medical charts. All collected data will be retrospective at time of extractions. Study Population: Patients diagnosed with an unresectable stage III NSCLC, having not progressed after a CRT and who have received at least one dose of durvalumab following the CRT within the EAP will be the target population. Exposure(s): Clinical characteristics, details of treatments (previous therapies, subsequent therapies), durvalumab exposure and serious AESIs Primary Outcome(s): PFS and OS. Sample Size Estimations: A target of 140 patients is estimated in the study.

Study Type

OBSERVATIONAL

Enrollment

106

Conditions

Carcinoma, Non-Small-Cell Lung

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: 1. Written informed consent or any locally required authorisation obtained from the patient prior to performing any protocol-related procedures 2. Adult of age ≥ 20 years at time of study entry 3. Patients must have been enrolled in one of the Pacific durvalumab EAPs Exclusion Criteria: 1\. Patients treated with durvalumab in clinical studies prior to the index date (first dose of durvalumab received within the EAP).

Locations (12)

National Taiwan University Hospital-Hsinchu Branch

Hsinchu, Taiwan

Chang Gung Medical Foundation-Kaohsiung Branch

Kaohsiung City, Taiwan

Chang Gung Medical Foundation-Keelung Branch

Keelung, Taiwan

Outcomes

Primary Outcomes

Progression free survival (PFS)

Defined as the time from initiation of the durvalumab therapy (index date) until earliest record of disease progression (including metastatic disease) determined by physicians' assessment, metastatic recurrence or death (if no progression) or end of follow-up (for censored observations)

Time frame: time from initiation of the durvalumab therapy (index date) until earliest record of disease progression (estimate assessed up to 3 years)

Overall survival (OS)

Defined as the time from durvalumab initiation date up to death or last date the patient was known to be alive (for censored observations).

Time frame: time from durvalumab initiation date up to death or last date the patient was known to be alive (estimate assessed up to 5 years)

Secondary Outcomes

Safety measures with retrospective collection of AESIs

* Require concomitant use of systemic corticoids, immunosuppressants and/or endocrine therapies, or * Leading to durvalumab temporary interruption, or * Leading to durvalumab permanent discontinuation.

Time frame: time from initiation of durvalumab therapy until stop treatment (assessed up to 3 years)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.